Last reviewed · How we verify
LIVACT
At a glance
| Generic name | LIVACT |
|---|---|
| Also known as | branched-chain amino acid, Branched chain amino acid |
| Sponsor | Kochi University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (PHASE4)
- The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites (PHASE4)
- Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIVACT CI brief — competitive landscape report
- LIVACT updates RSS · CI watch RSS
- Kochi University portfolio CI